Holen Sie sich die Stockscreener-App
614.25
2.07%
12.61
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Regeneron-backed Parabilis rises on market debut (REGN:NASDAQ) - Seeking Alpha
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Parabilis Medicines Raises $670 Million in Initial Public Offering - Pharmaceutical Executive
How WHO’s Maftivimab Priority for Bundibugyo Trials At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) stock price, news, quote and history - Yahoo Finance Singapore
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak - Insider Monkey
Parabilis Medicines targets $2.3 billion valuation in upsized US IPO - marketscreener.com
Allergic Rhinitis Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight - Barchart.com
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities - Seeking Alpha
5 Best Healthcare Stocks to Buy with Highest Upside Potential - Insider Monkey
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Daiwa Securities Group Inc. Sells 2,058 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court - Law360
Regeneron Pharmaceuticals Inc stock (US7739031091): valuation metrics in focus after recent trading - AD HOC NEWS
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein - The National Law Review
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Alvotech targets J&J’s Simponi and Regeneron’s Eylea (ALVO) - Seeking Alpha
Cambridge biotech plans $450M IPO with Regeneron backing - The Business Journals
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics - Yahoo Finance
With Strong Cash Flow, Regeneron Pharmaceuticals Stock Poised to Rise? - Trefis
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
2026-06-04 | Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
CytomX expands collaboration with Regeneron - The Pharma Letter
Regeneron backed Parabilis seeks up to $476M in U.S. IPO - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold? - Yahoo! Finance Canada
Regeneron to present clinical data at diabetes and endocrine meetings By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by TD Asset Management Inc - MarketBeat
Regeneron to present clinical data at diabetes and endocrine meetings - Investing.com
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets - BioSpace
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO - The Manila Times
Obesity and ultra-rare bone disease data from Regeneron at June conferences - Stock Titan
Sound Shore Management Inc. CT Has $135.76 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
CytomX stock jumps on $37M Regeneron collaboration payment - Investing.com
Regeneron and CytomX extend cancer therapy partnership to $4bn deal - Pharmaceutical Technology
CIBC Asset Management Inc Acquires 10,329 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bank of New York Mellon Corp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strong Cash Yield: Is Regeneron Pharmaceuticals Stock A Buy? - Trefis
How Investors May Respond To Regeneron (REGN) EMA Fast-Track Review Of Otarmeni Gene Therapy - Yahoo Finance
CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron - TipRanks
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
CytomX (NASDAQ: CTMX) adds programs, gains $37M from Regeneron - Stock Titan
Why Regeneron (REGN) Stock Is Trading Up Today - The Globe and Mail
CytomX Therapeutics (CTMX) Expands Collaboration with Regeneron Pharmaceuticals - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Regeneron rises 3.3% as investors focus on expanding oncology deal flow and bispecific R&D optionality - Quiver Quantitative
1.99%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):